Genetic polymorphisms as predictors of methotrexate toxicity: literature review
Background. A significant advancement in the treatment of high-grade aggressive non-Hodgkin’s lymphomas and acute lymphoblastic leukemia is the inclusion of high-dose (1000–5000 mg/m2) methotrexate in the treatment protocol. This approach has significantly increased the long-term survival rate, but...
Saved in:
Main Authors: | G. A. Radzhabova, T. T. Valiev, Yu. E. Ryabukhina, M. I. Savelyeva, Sh. P. Abdullaev, O. D. Gurieva, P. A. Zeynalova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2024-04-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/921 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possibilities of Predicting Methotrexate-associated Toxicity in Oncohematology Based on Molecular Genetic Testing Methods
by: Zarui K. Simavonyan, et al.
Published: (2024-11-01) -
Early toxicity of high-dose methotrexate in the treatment of non-hodgkin lymphomas in children
by: Z. K. Simavonyan, et al.
Published: (2025-03-01) -
Administration of high dose methotrexate monitoring a single serum methotrexate level at 72 hours
by: Saksham Singh, et al.
Published: (2025-06-01) -
Association of <i>SLCO1B3</i> and <i>SLCO1B1</i> Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients
by: Rania Magadmi, et al.
Published: (2025-07-01) -
Efficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis. Results of the multicenter “METEOR” study
by: V. N. Amirjanova, et al.
Published: (2025-03-01)